Clinical trial · Interventional
Exploring the Potential of Novel Biomarkers Based on Plasma microRNAs for a Better Management of Pelvic Gynecologic Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This trial is a non-randomized, open label and multicenter study. It aims to : for endometrial cancer.:validate the 5-miR index assessed in plasma samples as a diagnostic marker to assess the risk of lymph node metastases for ovarian cancer : to validate the previous finding on the prognostic value of the pre-/post-treatment variation of miR200b plasma concentrations with regards to PFS (the investigators mean the primary treatment including up-front or post-chemotherapy debulking and adjuvant chemotherapy).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sample | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- OTHER
- label
- Control
- description
- Patients undergoing surgery for benign pelvic lesions
- interventionNames
- Other: Blood sample
- type
- OTHER
- label
- Ovarian Cancer
- interventionNames
- Other: Blood sample
- type
- OTHER
- label
- Endometrial Cancer
- interventionNames
- Other: Blood sample
Primary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: For all patients (EC, OC, Control) * Written informed consent; * Age ≥ 18 years old; * Patient affiliated to social security. EC patients * Histologically proven EC ; * Type 1 and 2 EC; * FIGO stage I or II or III EC requiring first intention surgical staging. OC patients * Histologically proven OC or strong suspicion of OC on clinical arguments (abdomino-pelvian mass detected by palpation or echography and/or ascitis and/or elevated CA125); * Epithelial OC: any histological subtype; * FIGO stage I to IV OC. Control patients - Any lesion which is supposed to be benign and requires surgery. - Exclusion Criteria: For all patients (OC, EC, Control) * Unable or unwilling to comply with the protocol requirements and/or unwilling to sign an informed consent form. * Deprived of liberty or under legal protection measure; * Ongoing pregnancy; Control patients: \- Previous history of cancer. EC patients * FIGO stage IV at preoperative imaging techniques. * Previous history of cancer. OC patients * Non epithelial cancer. * Previous history of cancer - except for patients who developed breast cancer at least 5 years or more before ovarian cancer.
References
Publications (0)
Data not yet available